Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Viatris

3 Pharma Stocks Outperforming the Competition

The growing demand for innovative drugs, the use of advanced technologies, and growing global healthcare needs boost the pharmaceutical industry’s long-term growth prospects. Therefore, fundamentally strong pharma stocks Viatris (VTRS), Wave Life Sciences (WVE), and MEI Pharma (MEIP) might be ideal additions to your portfolio. Read on.

StockNews.com

Stock market today: Asia mixed after Wall St rallies ahead of US inflation update

Asian stocks are mixed after Wall Street rallied and Japanese wages rose ahead of a U.S. inflation update that might influence Federal Reserve plans for possible interest rate hikes

The Independent UK

Shield Therapeutics hails US market progress and mulls stateside listing

The Gateshead company said additional losses were to be expected as it carries out a plan to target US iron deficiency treatment demand

Birmingham Post

From analysis to the latest developments in health,
read the most diverse news in one place.

Shield Therapeutics revenues boosted by US sales of iron deficiency pills

The pharmaceuticals firm recently joined forced with Pennsylvania-based Viatris to tackle the American market

Birmingham Post

Shield Therapeutics secures £15.1m in raise and seals deal with healthcare company

The iron deficiency drug specialist will use the proceeds to mount a campaign on the US market

Birmingham Post

Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022

Upgrades

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Viatris (VTRS) Surpasses Q2 Earnings Estimates

Viatris (NASDAQ: VTRS) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.98 per share a year ago. These figures are adjusted for non-recurring items.

Benzinga

‘I was really struggling to get it up’: Why younger men are turning to Viagra

More men in their twenties and thirties are taking little blue pills for a variety of sexual ills, from erectile dysfunction to anxiety about their performance in the bedroom. Ben Bryant speaks to users, doctors and relationship counsellors about a very curious phenomenon

The Independent UK

Recession Investing: 5 High Yield Dividend Stocks For A Downturn

As the healthcare industry absorbed enormous amounts of profits during the Covid-19 pandemic, many healthcare companies will be increasing shareholder distributions to entice investors to buy their stock.

Benzinga

Median pay for executives at the largest companies surged last year. A few shareholders are crying foul

While it's surely not worth dwelling over, it nonetheless merits note: The highest-paid CEOs and their top-level colleagues rake in more money in one year — typically way more — than most of us will see in a lifetime.

Tribune News Service

Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022

Upgrades

Benzinga

Looking Into Viatris's Return On Capital Employed

According to Benzinga Pro, during Q1, Viatris (NASDAQ:VTRS) earned $399.20 million, a 251.33% increase from the preceding quarter. Viatris's sales decreased to $4.19 billion, a 3.45% change since Q4.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022

Upgrades

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Expert Ratings for Viatris

Analysts have provided the following ratings for Viatris (NASDAQ:VTRS) within the last quarter:

Benzinga

Viatris Posts Q1 Profit Despite 5% Dip In Sales, Reiterates FY22 Guidance Above Consensus

Viatris Inc (NASDAQ:VTRS) reported Q1 FY22 sales of $4.18 billion, down 5% Y/Y (-1% on an operational basis), below the consensus of $4.23 billion. Brands performed better than expectations, such as Lipitor, Effexor, and Perforomist. Complex generics and biosimilars grew by 21% Y/Y on an operational basis, driven mainly by the generic…

Benzinga

Viatris Q1 2022 Earnings Conference Call On May 9, 2022 At 08:30 AM ET

Viatris (NASDAQ:VTRS) will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022

Upgrades

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Viatris's Return On Capital Employed Overview

Benzinga Pro data, Viatris (NASDAQ:VTRS) reported Q4 sales of $4.34 billion. Earnings fell to a loss of $263.80 million, resulting in a 184.69% decrease from last quarter. Viatris earned $311.50 million, and sales totaled $4.54 billion in Q3.

Benzinga

Why Viatris Shares Are Trading Lower Today

Viatris Inc (NASDAQ: VTRS) is trading lower Monday after the company reported worse-than-expected top-line results for the fourth quarter and issued guidance below estimates.

Benzinga

Viatris To Pay $264M As EpiPen Antitrust Litigation Settlement: Reuters

Viatris Inc (NASDAQ: VTRS), previously known as Mylan, has

Benzinga

India-Based Biocon To Buy Viatris' Biosimilars Assets In $3.3B Deal

Biocon Biologics Ltd has agreed to acquire Viatris Inc's (NASDAQ:VTRS) biosimilars assets for up to $3.335 billion in stock and cash. The deal value includes cash of up to $2.335 billion and Compulsorily Convertible Preference Shares in Biocon Biologics, valued at $1 billion. Viatris will also pay $50 million to Biocon Biologics to fund…

Benzinga

A Bullish Sign Appears On Viatris's Chart

If history is any guide, there may be good fortune ahead for shares of Viatris (NASDAQ:VTRS). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Benzinga

Viatris Recalls One Batch Of Diabetes Treatment Semglee Citing Missing Label Risks

Viatris Inc's (NASDAQ: VTRS) Mylan will pull one batch of non-interchangeable Semglee, also known as insulin glargine injection.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.